Comparative Pharmacology
Head-to-head clinical analysis: OCUFEN versus PROLENSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OCUFEN versus PROLENSA.
OCUFEN vs PROLENSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation and pain.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and angiogenesis in the eye.
1 drop of 0.03% solution in the affected eye(s) four times daily beginning 24 hours after cataract surgery.
Adults: 1 drop in affected eye(s) twice daily (morning and evening) for 2 weeks.
None Documented
None Documented
1.2 to 2.0 hours (topical administration in ocular tissues); systemic half-life is 1.1 to 1.4 hours.
Terminal elimination half-life is approximately 1.5 hours for the ocular route; after systemic absorption, half-life is about 4.5 hours. The short half-life limits systemic exposure but requires multiple daily dosing for sustained ocular effect.
Urinary excretion of unchanged drug accounts for approximately 82% of a topical dose; fecal excretion is minor (<5%).
Primarily renal elimination (approximately 70% of the dose as unchanged drug and metabolites), with the remainder excreted in feces via biliary secretion (approximately 30%).
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID